Thermo Fisher Scientific Expands HeavyPeptide Collection, Offering Customers Greater Value and Choice

Source : Thermo Fisher Scientific Inc.

ULM, Germany (August 24, 2009) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it is expanding its industry-leading offering of HeavyPeptide kits for quantification of proteins through mass spectrometry. Providing customers with greater value and choice, the expanded Thermo Scientific HeavyPeptide Aqua™ line will debut at the 8th Annual World Congress of the Human Proteome Organisation (HUPO) in Toronto, Sept. 26-30. The collection includes:

  • HeavyPeptide AQUA Ultimate™ — the industry standard for absolute quantification, delivered in solution with known concentration and a precision level of +- 5 percent.

  • HeavyPeptide AQUA QuantPro™ — a more affordable alternative when ultimate precision is not necessary.

  • HeavyPeptide AQUA Basic — competitively priced and designed for customers engaged in relative quantification who prefer to work with lyophilized (powdered) products.

“With this expanded range of products, we are giving customers the choice of precision, grade and price,” said Joel Louette, commercial director for Thermo Scientific Custom Biopolymers.

In addition, the company continues to offer the Thermo Scientific HeavyPeptide™ FasTrack service to accelerate initial peptide selection and purification. The service provides customers with a choice of crude heavy peptides to develop their mass spectrometry assays and identify the best proteotypic peptide candidates. Once a customer has identified these candidates, retained crude stock is used to quickly produce the final purified heavy peptides to be used in the experiments. Crude heavy peptides are also now available independent of the FasTrack service.

The new HeavyPeptide AQUA offering will be exhibited during the HUPO Congress at Toronto’s Westin Harbour Castle. Members of the Thermo Scientific Custom Biopolymers team will be available to answer customer questions. While supplies last, vouchers for free HeavyPeptide AQUA sample kits will also be available.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With 2008 revenues of $10.5 billion, we have approximately 34,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. The Thermo Scientific brand represents a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit


  • <<
  • >>

Articles List

  • Chromatin Dynamics: Tracking Epigenomic Status Over Time

    Chromatin Dynamics: Tracking Epigenomic Status Over Time

    In essence, chromatin-dynamics studies are simply epigenomic datasets collected over time, typically via either genome-scale chromatin immunoprecipitation (ChIP-Seq) or DNA methylation analysis (bisulfite sequencing). Here are some of your options.
  • Chromosomes Customized While-U-Wait with Genome-Editing Services

    Chromosomes Customized While-U-Wait with Genome-Editing Services

    With each new technical advance, genome editing becomes ever more accessible. Yet it’s still not a trivial matter to create a homogenous cell line with a targeted disruption, and even less so with a gain-of-function mutation, and any researchers have turned to commercial companies and university core facilities, practiced in the art and armed with the most up-to-date knowledge, to help. Here’s what you can expect.

Disqus Comments